Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, Zhejiang Province, People's Republic of China.
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, People's Republic of China.
Cancer Immunol Res. 2022 Jul 1;10(7):811-828. doi: 10.1158/2326-6066.CIR-21-1101.
Intrahepatic cholangiocarcinoma (ICC) is a relatively rare but highly aggressive tumor type that responds poorly to chemotherapy and immunotherapy. Comprehensive molecular characterization of ICC is essential for the development of novel therapeutics. Here, we constructed two independent cohorts from two clinic centers. A comprehensive multiomics analysis of ICC via proteomic, whole-exome sequencing (WES), and single-cell RNA sequencing (scRNA-seq) was performed. Novel ICC tumor subtypes were derived in the training cohort (n = 110) using proteomic signatures and their associated activated pathways, which were further validated in a validation cohort (n = 41). Three molecular subtypes, chromatin remodeling, metabolism, and chronic inflammation, with distinct prognoses in ICC were identified. The chronic inflammation subtype was associated with a poor prognosis. Our random forest algorithm revealed that mutation of lysine methyltransferase 2D (KMT2D) frequently occurred in the metabolism subtype and was associated with lower inflammatory activity. scRNA-seq further identified an APOE+C1QB+ macrophage subtype, which showed the capacity to reshape the chronic inflammation subtype and contribute to a poor prognosis in ICC. Altogether, with single-cell transcriptome-assisted multiomics analysis, we identified novel molecular subtypes of ICC and validated APOE+C1QB+ tumor-associated macrophages as potential immunotherapy targets against ICC.
肝内胆管癌(ICC)是一种相对罕见但高度侵袭性的肿瘤类型,对化疗和免疫疗法反应不佳。全面的 ICC 分子特征对于新型治疗方法的开发至关重要。在这里,我们从两个临床中心构建了两个独立的队列。通过蛋白质组学、全外显子测序(WES)和单细胞 RNA 测序(scRNA-seq)对 ICC 进行了全面的多组学分析。使用蛋白质组学特征及其相关激活途径,在训练队列(n = 110)中衍生出新的 ICC 肿瘤亚型,并在验证队列(n = 41)中进一步验证。在 ICC 中,确定了三个具有不同预后的分子亚型,即染色质重塑、代谢和慢性炎症。慢性炎症亚型与预后不良相关。我们的随机森林算法表明,赖氨酸甲基转移酶 2D(KMT2D)的突变经常发生在代谢亚型中,与较低的炎症活性相关。scRNA-seq 进一步鉴定了一种 APOE+C1QB+巨噬细胞亚型,该亚型具有重塑慢性炎症亚型的能力,并导致 ICC 预后不良。总的来说,通过单细胞转录组辅助的多组学分析,我们确定了 ICC 的新型分子亚型,并验证了 APOE+C1QB+肿瘤相关巨噬细胞作为针对 ICC 的潜在免疫治疗靶点。